TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01164306

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LifeSkills Training
Description: LifeSkills Training (Botvin's) is an evidenced based substance abuse prevention program for elementary school students to learn skills to resist tobacco, alcohol, drug abuse, and violence.~Parent LifeSkills will also be utilized. Parents are provided a parent manual and DVD to use at home with their child to reinforce what they are taught in school-based LifeSkills sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Lifestyle Behavior Choices
Description: The healthy lifestyle behavior choices curriculum augments the state health curriculum in the assigned study schools.~Parents will also be given health related information by mail to parallel the information students receive in school health classes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NRT and Motivational Interviewing (MI)
Description: For parent/guardian smokers who want to quit, NRT is offered in conjunction with MI.
Study: NCT02545647

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BRYGB
Description: 65 patients undergo a banded RYGB
Study: NCT01829919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brisdelle (paroxetine mesylate)
Description: All subjects will receive Brisdelle (paroxetine mesylate) Capsules 7.5 mg, first as a single dose and then, following a five-day wash-out period, once per day for 14 days.
Study: NCT03744221

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Corn protein powder
Description: 40g/d ( 2 times 20 grams per day for a period of 1 week)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bovine plasma protein powder
Description: 40g/d ( 2 times 20 grams per day for a period of 1 week)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey protein powder
Description: 40g/d ( 2 times 20 grams per day for a period of 1 week)
Study: NCT03046498

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evidence-Based Program
Description: DSMP and DPP
Study: NCT02712801

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zidovudine
Description: Dose will be adjusted according to the child's weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine
Description: Dose will be adjusted according to the child's weight.
Study: NCT02076321

Intervention type: DRUG
Group type: OTHER
Intervention: Acetaminophen
Description: acetaminophen for pain control with dose and frequency of 10-15mg/kg/dose, Maximum dose 1000mg. Maximum amount per day: 75mg/kg (not to exceed 4g/day).

Intervention type: DRUG
Group type: OTHER
Intervention: Ibuprofen
Description: ibuprofen for pain control with dose and frequency 4-10mg/kg/dose. Maximum of 40mg/kg/day, not to exceed 3,200mg/day. Maximum one-time dose of 800mg.
Study: NCT02586753

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus Cisplatin with radiotherapy
Description: we want to compare which regime is better with radiotherapy, PT regime (paclitaxel and cisplatine ) Chemotherapy: Patients will be concurrently administered with irradiation every 3 weeks with PT regimen (cisplatin of 20 mg/m2/d, d1-3; PTX(paclitaxel)of 135mg/m2/d, d1) for 4 cycles. For the first 2-cycles of chemotherapy they will be concurrently given with irradiation and the remained 2 cycles, after irradiation.~Radiotherapy:Patients will be conducted CT simulation, and Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 60-66Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: S1 plus Cisplatin with radiotherapy
Description: we want to compare which regime is better with radiotherapy,SP regime (Tegafur Gimeracil Oteracil Potassium Capsule and cisplatine).~Chemotherapy: Patients will be concurrently administered with irradiation every 3 weeks with PS regimen (cisplatin of 20 mg/m2/d, d1-3; S1(Tegafur Gimeracil Oteracil Potassium Capsule)of 50mg/m2/d, d1-14) for 4 cycles. For the first 2-cycles of chemotherapy they will be concurrently given with irradiation and the remained 2 cycles, after irradiation.~Radiotherapy:Patients will be conducted CT simulation, and Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 60-66Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator.
Study: NCT02602938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Take aspirin (100mg) orally once a day for 2 months
Study: NCT02712801

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine
Description: Dose will be adjusted according to the child's weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: Dose will be adjusted according to the child's weight.
Study: NCT02891525

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 250mL tap water
Study: NCT04183959

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: video stylet
Description: trachea will be intubated using laryngoscopic assisted video stylet device in lateral position
Study: NCT02304315

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1102 50,000 IU
Description: a recombinant hepatitis B immunoglobulin
Study: NCT04183959

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fiberoptic
Description: intubation will be done using fiberoptic device by the same anesthesiologist in lateral position
Study: NCT04661410

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reward Re-Training
Description: A brief, 10-session group-based behavioral treatment that is designed to indirectly change binge eating by directly focusing on building a more rewarding life. RRT hypothesizes that reductions in binge eating will occur as life becomes more rewarding because individuals will no longer need to rely on binge eating as a primary source of momentary reward. RRT notes that in order to live a satisfying life, individuals need to experience an adequate amount of reward in two overlapping yet distinguishable domains: momentary reward (i.e., the active experience of pleasure in the moment) and sustained reward (i.e., a deeper and more long-lasting sense of fulfillment and meaning that arises from building a personally valued life). A key aspect of RRT is an emphasize on building lasting and meaningful social relationships given the clear evidence that social connectedness can enhance both momentary reward and sustained reward.
Study: NCT02304315

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1102 80,000 IU
Description: a recombinant hepatitis B immunoglobulin
Study: NCT04099732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1358894
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1358894
Description: Tablet
Study: NCT04661410

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Therapy
Description: A brief, 10-session group-based treatment that is designed to instill hope and optimism and to increase social connection and support through a non-directive group leader that allows the patients to determine the focus of each session. The group leader will act as an empathetic provider by using reflective listening, eliciting and validating affect, and offering empathic comments.
Study: NCT04148040

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: G-POEM
Description: Per-oral pyloromyotomy (POP), also named as gastric per-oral endoscopic myotomy (G-POEM), for treating infantile hypertrophic pyloric stenosis (IHPS) has the following steps: mucosal incision, creation of submucosal tunnel, full-thickness pyloromyotomy, closure of the mucosal entry.
Study: NCT00841035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: Preoperative dosing of 150 mg oral erlotinib for 7 days before surgery. followed by erlotinib 100 mg daily 6 month/6 chemotherapy cycles. Gemcitabine 1000 m2 weekly after surgery for 6 cycles.
Study: NCT03639350

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IER+MED group
Description: Follow a Mediterranean diet 5 days per week and follow intermittent energy restriction 2 days per week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DASH group
Description: Follow the distribution of macronutrients and food groups prescribed by the DASH diet 7 days per week.
Study: NCT03470662

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care bundle
Description: Care bundle
Study: NCT01972763

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Ranibizumab is formulated as a sterile solution and will be used in the case of an intervention.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Ranibizumab is formulated as a sterile solution and will be used in the case of an intervention.
Study: NCT04305405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Dose will be stratified by body weight at screening: Patients will receive Dose 1 or Dose 2 of Benralizumab administered by SC injection at Day 0 and Weeks 4, 8, and 16, 24, 32, and 40.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Dose will be stratified by body weight at screening: Patients will receive Dose 1 or Dose 2 of Benralizumab administered by SC injection at Day 0 and Weeks 4, 8, and 16, 24, 32, and 40.
Study: NCT03932981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide at a monthly standard dose of 150-200 mg/m2/day at day 1 to day 5 for a duration of treatment of 12 months
Study: NCT00223587

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1 week of treatment discontinuation
Description: 1 week of treatment discontinuation during allergic rhinitis season
Study: NCT02083575

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C, Defriprone, deferisarox
Description: adjuvant vitamin c with iron chelator.

Intervention type: DRUG
Group type: OTHER
Intervention: deferiprone , deferesarox
Description: iron chelator
Study: NCT03007147

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo HSCT
Study: NCT03914859

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: IN VITRO FERTILIZATION
Description: Using exposure biomarker as a reliable means of evaluating gamete quality to estimate the chances of success in in vitro fertilization.
Study: NCT03007147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calaspargase Pegol
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calaspargase Pegol
Description: Given IV
Study: NCT00529659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK-0773
Description: MK-0773 50 mg tablets twice daily, 6 month treatment period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo tablets twice daily, 6 month treatment period
Study: NCT00064012

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bortezomib
Study: NCT04099732

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: Capsule
Study: NCT00454155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opebacan
Description: 4 mg/kg continuous IV infusion for 30 minutes followed immediately by 6 mg/kg/day continuous IV infusion for 3 days
Study: NCT03745196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PC945
Description: Study drug under investigation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control
Study: NCT03215654

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EspaiJove.net mental health literacy program
Description: The EspaiJove.net: a space for mental health (EspaiJove.net) project is a MHL program which aims the promotion of mental health, the prevention of mental disorders, the facilitation of help-seeking behaviors and the eradication of stigma among secoundary students into the Spanish context.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EspaiJove.net mental health literacy program
Description: The EspaiJove.net: a space for mental health (EspaiJove.net) project is a MHL program which aims the promotion of mental health, the prevention of mental disorders, the facilitation of help-seeking behaviors and the eradication of stigma among secoundary students into the Spanish context.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EspaiJove.net mental health literacy program
Description: The EspaiJove.net: a space for mental health (EspaiJove.net) project is a MHL program which aims the promotion of mental health, the prevention of mental disorders, the facilitation of help-seeking behaviors and the eradication of stigma among secoundary students into the Spanish context.
Study: NCT03007147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calaspargase Pegol
Description: Given IV
Study: NCT00804739

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mother-Infant Treatment Team
Description: This is a treatment team approach that allows for outreach. The clinical team will be a nurse practitioner of psychiatry and a social worker. The nurse practitioner will provide either interpersonal psychotherapy, sertraline or both as indicated.
Study: NCT02618980

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: endoscopic hemostasis
Description: At endoscopy, stigmata of hemorrhage (SRH) will be treated by dual endoscopic local therapy (combining at least two of the following treatments: epinephrine injection, coaptive thermocoagulation, hemoclip therapy, argon plasma coagulation, bipolar coagulation).
Study: NCT01737840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: 33 patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranitidine
Description: 33 patients
Study: NCT00064012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Study: NCT01040208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flibanserin 50 mg to 100 mg qhs
Description: 50 to 100mg qhs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flibanserin 100 mg qhs
Description: 100mg qhs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo 2 tablets qhs
Description: 50 mg placebo
Study: NCT02413619

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vitrectomy
Description: Vitrectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract surgery
Description: Cataract surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combined surgery
Description: Combined vitrectomy and cataract surgery at the same time
Study: NCT01673503

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carl Zeiss Meditech VisuMax laser
Description: Refractive lenticule extraction (ReLEx) with the Carl Zeiss Meditech VisuMax laser

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carl Zeiss Meditech VisuMax laser
Description: Refractive lenticule extraction (ReLEx) with the Carl Zeiss Meditech VisuMax laser
Study: NCT00122356

Intervention type: DRUG
Group type: OTHER
Intervention: Alendronate sodium
Description: 70mg tablets, once weekly
Study: NCT03425942

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet Cognitive Behavioral Therapy for insomnia (ICBT-i)
Description: This intervention lasts for five weeks. The intervention is internet-based and mainly consists of the most potent CBT technics i.e. sleep restriction and stimulus control. Weekly feedback is provided by master students supervised by clinical psychologists.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet Applied Relaxation Techniques (IART-i)
Description: This intervention lasts for five weeks. The intervention is internet-based and consists of different common applied relaxation exercises and treatments. Weekly feedback is provided by master students supervised by clinical psychologists.
Study: NCT02517827

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Atherectomy and paclitaxel-coated balloon angioplasty
Description: Directional atherectomy and paclitaxel-coated balloon angioplasty (optional with stentimplantation) of the common femoral artery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open, surgical endarterectomy
Description: open, surgical endarterectomy of the common femoral artery
Study: NCT02604927

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-alanine

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dextrose
Study: NCT04102878

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Anesthetic
Description: Topical anaesthetic drops (proxymetacaine 0.5% and tetracaine 1%) applied
Study: NCT00064012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study: NCT02099175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 - Concentrate for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 800 mg/m2/day - Concentrate for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 150 mg/m2/day - Concentrate for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Description: 20 mg/m2/day - Powder for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: 3000 mg/m2/day - Powder for solution for infusion
Study: NCT01544270

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Yogurt-like snacks
Description: twice a day 120 g for four weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Yogurt-like snacks
Description: twice a day 120 g for four weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Yogurt-like snacks
Description: twice a day 120 g for four weeks
Study: NCT02099175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 250 mg/m2/day - Powder for solution for infusion
Study: NCT04102878

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transconjunctival anaesthetic
Description: Local anaesthetic (50/50 mixture of bupivacaine 0.5% / lidocaine 2% with adrenaline 1:200 000) administered to the eyelid via the transconjunctival route

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous anaesthetic
Description: Local anaesthetic (50/50 mixture of bupivacaine 0.5% / lidocaine 2% with adrenaline 1:200 000) administered to the eyelid via the transcutaneous route

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous anaesthetic
Description: Local anaesthetic (50/50 mixture of bupivacaine 0.5% / lidocaine 2% with adrenaline 1:200 000) administered to the eyelid via the transcutaneous route

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient comfort questionnaire
Description: The patient will be asked to rate the level of pain during each local anaesthetic injection on a 0-10 scale

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient comfort questionnaire
Description: The patient will be asked to rate the level of pain during each local anaesthetic injection on a 0-10 scale

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Facial photograph
Description: The patient will have a photograph taken following the anaesthetic injections to document the presence or absence of bruising

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Facial photograph
Description: The patient will have a photograph taken following the anaesthetic injections to document the presence or absence of bruising
Study: NCT03007147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV, SC, or IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV, SC, or IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV, SC, or IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV
Study: NCT04102878

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Eyelid surgery
Description: Eyelid surgery will be performed as per the plan from their preoperative appointment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Eyelid surgery
Description: Eyelid surgery will be performed as per the plan from their preoperative appointment
Study: NCT01821820

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pistachios
Study: NCT00002833

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Donors receive Filgrastim SC (Subcutaneously) every 12 hours for 2 days prior to stem cell collection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Donors receive Filgrastim SC (Subcutaneously) every 12 hours for 2 days prior to stem cell collection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Continuous infusion for 5 days, beginning 4 hours before Ara-C first dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: For GVHD prophylaxis, cyclosporine via continuous IV infusion. Oral cyclosporine administered once tolerating oral feeding and continued for 6 months postinfusion. Then dose tapered 10% weekly until discontinued.
Study: NCT02808585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB1046 Injection
Description: Four weekly subcutaneous injections of PB1046.